Acturadar.comFrance in real time

Detected on Tuesday 17 November, 19h00

Sanofi relocates production of type 1 diabetes treatment to Lyon

Sanofi has transferred to France, at its Lyon Gerland site, the production of a biotherapy for type 1 diabetes acquired from the United States in 2023. The group presents this relocation as a commitment to health sovereignty.

In brief

Economy event (severity: notable) in Lyon Gerland (Rhône), first detected on 17 November 2026 at 19:00. Reported by 1 source (1 article), last updated on 17 November 2026 at 19:00.

·
Category
Economy
Severity
Notable
Place
69 RhôneLyon Gerland
Detected
17 Nov, 19h00
Updated
17 Nov, 19h00
Reference
no.23228
01

Who is covering it, and from what angle

Method
1Centre

1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 1, right 0

Angle comparison

A comparison is written as soon as the event is covered by at least two sides (left, centre, right).

02

Lire les sources · 1 article, 1 source

Publication order
  1. 19h00
    Le ProgrèsCentreWire17 Nov
    Santé. Comment Sanofi a relocalisé un médicament contre le diabète à Lyon

    En 2023, Sanofi a acquis aux États-Unis le premier traitement capable de retarder l’apparition au stade clinique du diabète de type 1. Le géant pharmaceutique a alors décidé de transférer en France, sur son site de Lyon Gerland, la production de cette biothérapie. Une illustration de l’engagement de Sanofi en faveur de la souveraineté sanitaire, expliquent ses responsables.

03

Further reading

Organisations cited

Keywords

#Sanofi · #relocalisation · #diabète

Go up the thread

Affected departments

People and organisations cited